University of California San Francisco, San Francisco, CA
Charles Chu , Albert Y. Lin
Background: Colon cancer remains one of the leading causes of cancer death worldwide. There has been a renewing interest in the role of PTL (right- or RS vs. left-sided or LS) in CC for their differences in biology, prognostic and predictive features. Given the increasing incidence of early-onset (age 20-49) CC, coupled with their longer life expectancy, we seek to examine the effects of PTL and age in the development of SPM in a population-based cohort. Methods: Surveillance, Epidemiology, and End Results (SEER) Program data were queried to identify CC PTS diagnosed between 1973-2015 with complete follow-up information and available data on SPM. Using SEER*Stat, we calculated standardized incidence ratios (SIRs) -- the ratio of observed to expected cases of SPM based on incidence data in the general US population and compared by PTL (RS vs. LS) and age of diagnosis (20-49 vs. >49). Results: A total of 269,442 (RS/LS=46.4%/53.6%) CC PTS were obtained. Overall RS, compared with LS, CC PTS have a higher likelihood of developing SPM in all sites (OR: 1.09, 95% CI: 1.08- 1.11 vs. 1.03, 1.02-1.04). RS CC PTS and age 20-49 group, compared with other subgroups, has a much greater likelihood of being diagnosed with the following SPM:small intestine, urinary tract, bile duct, gynecologic (GYN), and stomach cancers, as shown in the Table below. Conclusions: Our results show that the increased risk in non-colonic SPMs in CC PTS is associated with RS CC and age less than 49, suggesting the implications on survivorship care and surveillance of SPMs. Furthermore, there may be a possible overlap with Lynch syndrome in these PTS with SPM given the overlap in the presentation of cancer patterns and early-onset of CC, suggesting the indication for MMR testing.
SPM | Age | RS |
LS |
||||
---|---|---|---|---|---|---|---|
SIR | 95% CI | SIR | 95% CI | ||||
Small intestine | 20-49 | 16.89 | 12.69 | 22.04 | 7.25 | 5.13 | 9.95 |
> 49 | 3.49 | 3.07 | 3.97 | 2.47 | 2.14 | 2.83 | |
Urinary tract cancer | 20-49 | 10.17 | 6.03 | 16.07 | 4.70 | 2.63 | 7.76 |
> 49 | 1.5 | 1.29 | 1.79 | 0.99 | 0.80 | 1.20 | |
Bile duct cancer | 20-49 | 5.49 | 3.20 | 8.79 | 2.89 | 1.65 | 4.70 |
> 49 | 1.32 | 1.12 | 1.54 | 1.22 | 1.05 | 1.42 | |
GYN cancer | 20-49 | 4.31 | 3.47 | 5.29 | 1.91 | 1.51 | 2.37 |
> 49 | 1.19 | 1.09 | 1.30 | 1.08 | 0.98 | 1.18 | |
Stomach | 20-49 | 3.48 | 2.42 | 4.84 | 1.97 | 1.35 | 2.76 |
> 49 | 1.18 | 1.08 | 1.30 | 1.13 | 1.03 | 1.23 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: M. Cecilia Monge B.
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Shodai Tohyama
2019 ASCO Annual Meeting
First Author: Eric Adjei Boakye
2022 ASCO Annual Meeting
First Author: Rongrong Wu